Who are Lipid Modifying Therapy (LMT)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Xuezhikang capsule, Omega-3-acid ethyl esters 90, EZE/simvastatin, Probucol group, Cilostazol + Probucol group, Cilostazol+Probucol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lipid-modifying-therapy-lmt.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Lipid Modifying Therapy (LMT) — Competitive Intelligence Brief

Lipid Modifying Therapy (LMT) (Lipid Modifying Therapy (LMT)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Lipid-lowering agent. Area: Cardiovascular.

phase 3 Lipid-lowering agent Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Lipid Modifying Therapy (LMT) (Lipid Modifying Therapy (LMT)) — Sanofi. Lipid Modifying Therapy reduces circulating lipid levels through modulation of lipid metabolism pathways to lower cardiovascular risk.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Lipid Modifying Therapy (LMT) TARGET	Lipid Modifying Therapy (LMT)	Sanofi	phase 3	Lipid-lowering agent
Xuezhikang capsule	Xuezhikang capsule	China Academy of Chinese Medical Sciences	marketed	Herbal lipid-lowering agent; statin-containing traditional Chinese medicine
Omega-3-acid ethyl esters 90	Omega-3-acid ethyl esters 90	Pronova BioPharma	marketed	Fibrate-like lipid-lowering agent / Omega-3 fatty acid
EZE/simvastatin	EZE/simvastatin	Azienda Ospedaliero Universitaria di Sassari	marketed	Combination lipid-lowering agent (ezetimibe + statin)	NPC1L1 transporter (ezetimibe); HMG-CoA reductase (simvastatin)
Probucol group	Probucol group	Otsuka Beijing Research Institute	marketed	Antioxidant lipid-lowering agent
Cilostazol + Probucol group	Cilostazol + Probucol group	Otsuka Beijing Research Institute	marketed	Antiplatelet agent + Antioxidant lipid-lowering agent	Phosphodiesterase-3 (cilostazol); LDL oxidation pathway (probucol)
Cilostazol+Probucol	Cilostazol+Probucol	Otsuka Beijing Research Institute	marketed	Antiplatelet agent + Antioxidant lipid-lowering agent	Phosphodiesterase-3 (cilostazol); Antioxidant mechanism (probucol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Lipid-lowering agent class)

Anja Bisgaard Pinborg · 1 drug in this class
OmegaD LLC · 1 drug in this class
Sanofi · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Lipid Modifying Therapy (LMT) — Competitive Intelligence Brief. https://druglandscape.com/ci/lipid-modifying-therapy-lmt. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab